HD-OPM Archive
Topics › Statins

JUPITER: rosuvastatin 20 mg brought diabetes diagnosis ~5.4 weeks earlier, A1C up 0.1

Louis Nervegna · Jul 11, 2025 · ♥ 2 reactions · 2 comments · original Facebook post
StatinsInsulin resistance & diabetes
↻ This is a repost. The main version (highest ranked) is In JUPITER, rosuvastatin brought diabetes diagnosis forward by only 5.4 weeks · Feb 13, 2024.
AI summary & key facts

Louis uses the JUPITER trial (20 mg rosuvastatin vs placebo, 17,600 people, up to 5 years) to quantify statin-related diabetes risk. Statin allocation accelerated diabetes diagnosis by 5.4 weeks on average and raised HbA1c by 0.1 at 24 months, which he calls clinically meaningless relative to cardiovascular benefit.

(no text — see the shared post below)

Research cited

How much do statins increase the risk for diabetes in humans?

Let’s look at the JUPITER randomized controlled trial which tested 20mg rousuvastin vs placebo in 17,600 people for up to 5 years.

This was the largest clinical trial ever conducted which examined the relationship between statins and blood sugar.

If you took the statin instead of placebo in this trial, you could expect to be diagnosed with diabetes 5.4 weeks earlier than you would have otherwise if taking the placebo, on average. And you could expect to see an increase in A1C of about 0.1 after 2 years on the drug.

The bottom line is that no one got diabetes in this trial who was not going to get it anyway. They just got it about 5 weeks earlier, over a period of up to 5 years. This is clinically meaningless. And 20mg is a high dose of rousuvastatin. Most people take 5mg in real life.

Quoted:

“As compared to placebo, statin allocation accelerated the average time to diagnosis of diabetes by 5.4 weeks.”

“As also shown, among those with and without diabetes risk factors, measured HbA1c at 24 months increased by 0.1 percent among those allocated to rosuvastatin (both p-values 0.001).”

Paper · Lancet · 2012Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.Conclusion: In the JUPITER primary prevention trial, the cardiovascular and mortality benefits of statin therapy exceed the diabetes hazard, including in participants at high risk of developing diabetes.ncbi.nlm.nih.gov

#jupiterHD #statindiabetesHD #statinsHD

← newer: Statin relative vs absolute risk: a 1.1-4.7% drop in 5 yearsolder: Following AHA Life's Essential 8 for ~10 years linked to 66% →